Title : Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.

Pub. Date : 2014 Dec

PMID : 25463129






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: LDL-C percent change from baseline was -26.0 for ezetimibe added to ongoing statin therapy, -27.6 for switching from ongoing statin to ezetimibe/simvastatin, -19.7 for switching to rosuvastatin 10 mg, and -9.7 for dose doubling of the ongoing statin. Simvastatin component of oligomeric golgi complex 2 Homo sapiens
2 For patients within 0.8 mmol/L (30 mg/dL) of the target at baseline, LDL-C target attainment rates were 75.9% for adding ezetimibe to ongoing statin, 72.8% for switching to ezetimibe/simvastatin, 61.8% for switching to rosuvastatin, and 44.3% for statin dose-doubling. Simvastatin component of oligomeric golgi complex 2 Homo sapiens